autoimmune-mediated psychiatric syndromes
Conditions
Interventions
Group 1: Retrospective analysis of all psychiatric patients who underwent serum/cerebrospinal fluid autoimmune analysis between 2015 and 2025. Cases with abnormalities (specific antibodies/positive sc
Sponsors
Universitätsklinikum Bonn
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Abnormalities in cerebrospinal fluid (CSF) in autoimmune diagnostics / Control group: Serum and CSF unremarkable.
Exclusion criteria
Exclusion criteria: without
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the detection of specific symptom/syndrome clusters in the patient cohort studied. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are clusters in the treatment approaches undertaken (pharmacological and non-pharmacological) and their success/failure. | — |
Countries
Germany
Contacts
Public ContactDavid Vogel
Universitätsklinikum Bonn
Outcome results
None listed